GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2013

Sanofi Presents Encouraging Phase III Data for Myelofibrosis Drug

  • Sanofi today announced that its randomized, double-blind, placebo-controlled Phase III JAKARTA study evaluating its investigational JAK2 kinase inhibitor SAR302503 for myelofibrosis has met its primary endpoint—of patients achieving greater than or equal to 35% reduction of spleen volume—in both dose groups.

    “I am pleased with the results of JAKARTA,” Debasish Roychowdhury, M.D., svp and head, Sanofi Oncology, said in a statement. “Since Sanofi's acquisition of the molecule, SAR302503 has moved from Phase I to the completion of pivotal Phase III studies in less than three years, and now we are planning regulatory filings with authorities to make this medicine available for patients,” Dr. Roychowdhury added.

    Sanofi acquired the drug candidate in 2010 when it snapped up small molecule drug development firm TargeGen.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?